Chih-Lang Lin

Dr. Chih-Lang Lin


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2012 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
CCChin-Ying Chien
Chin-Ying Chien
CHCheng-Cheng Hwang
Cheng-Cheng Hwang
CYChun-Nan Yeh
Chun-Nan Yeh
HCHuang-Yang Chen
Huang-Yang Chen
JWJui-Teng Wu
Jui-Teng Wu
KCKun-Chun Chiang
Kun-Chun Chiang
Liver angiosarcoma is a rare disease, however it still ranks as the third of most common primary liver maligancies. The prognosis of liver angiosarcoma is very poor with almost all patients with this kind of disease die within 2 years after diagnosis. No specific symptoms and signs are closely associated with this disease. Here, we report a case presenting shock status at first due to rupture of liver angiosarcoma- induced internal bleeding. After emergent transarterial embolization (TAE), she received partial hepatectomy two weeks later. 4 months after operation, she is still with a good performance status without obvious recurrence or metastasis identified.

9 February 2019 in Journal of Viral Hepatitis
Verified
Journal Article
Closed access
PDF file
YSYu-Chiau Shyu
Yu-Chiau Shyu
THTing‐Shuo Huang
Ting‐Shuo Huang
CCCheng‐Hung Chien
Cheng‐Hung Chien
CYChau-Ting Yeh
Chau-Ting Yeh
CLChih-Lang Lin
Chih-Lang Lin
Rong-Nan ChienRong-Nan Chien
Rong-Nan Chien

20 March 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MLMing-Wei Lai
Ming-Wei Lai
YCYu-De Chu
Yu-De Chu
CLChih-Lang Lin
Chih-Lang Lin
Rong-Nan ChienRong-Nan Chien
Rong-Nan Chien
TYTa-Sen Yeh
Ta-Sen Yeh
CYChau-Ting Yeh
Chau-Ting Yeh
Although men carry a higher risk of hepatocellular carcinoma (HCC) than women, it is still controversial whether men also have a poorer postoperative prognosis. A retrospective study was conducted to evaluate the postoperative prognostic predictors of HCC focusing on sex differences. We enrolled 516 consecutive adult patients with HCC (118 women, 398 men), who received surgical resection between January 2000 and December 2007, and were followed-up for >10 years. Clinical and laboratory data together with postoperative outcomes were reviewed. At baseline, female patients had a higher anti-hepatitis C virus antibody prevalence (P = 0.002); lower hepatitis B virus surface antigen prevalence (P = 0.006); less microvascular invasion (P = 0.019); and lower alpha-fetoprotein (P = 0.023), bilirubin (P = 0.002), and alanine transaminase (P = 0.001) levels. Overall, there were no significant sex differences in terms of intrahepatic recurrence-free survival (RFS), distant metastasis-free survival (MFS), and overall survival (OS). However, subgroup analysis showed that women had favorable RFS (P = 0.019) and MFS (P = 0.034) in patients with alpha-fetoprotein ≤ 35 ng/mL, independent of other clinical variables (adjusted P = 0.008 and 0.043, respectively). Additionally, men had favorable OS in patients with prothrombin time (international normalized ratio [INR]) <1.1 (P = 0.033), independent of other clinical variables (adjusted P = 0.042). Female sex is independently associated with favorable postoperative RFS and MFS in patients with alpha-fetoprotein ≤35 ng/mL, while male sex is independently associated with favorable OS in patients with prothrombin time INR <1.1.

6 October 2014 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
CLChih-Lang Lin
Chih-Lang Lin
RCRong-Nan Chien
Rong-Nan Chien
CYCharisse Yeh
Charisse Yeh
CHChao-Wei Hsu
Chao-Wei Hsu
MCMing-Ling Chang
Ming-Ling Chang
CYChau-Ting Yeh
Chau-Ting Yeh
Objective. Cisplatin is a known nephrotoxic agent requiring vigorous hydration before use. However, aggressive hydration could be life-threatening. Therefore, in cirrhotic patients with advanced hepatocellular carcinoma (HCC) under cisplatin-based chemotherapy, the risk of nephrotoxicity increased. Because previous studies showed that long-term telbivudine treatment improved renal function in chronic hepatitis B virus (HBV) infected patients, we conducted a case–control study to evaluate the clinical outcome of telbivudine preemptive therapy in HBV-related advanced HCC patients treated by combination chemotherapy comprising 5-fluorouracil, mitoxantrone and cisplatin (FMP). Material and methods. From June 2007 to March 2012, 60 patients with HBV-related advanced HCC, all receiving the same FMP chemotherapy protocol, were enrolled. Of them, 20 did not receive any antiviral therapy, whereas the remaining 40 patients (sex and age matched) received telbivudine preemptive therapy. Results. Progressive decrease of aminotransferase levels (p < 0.05) and progressive increase of viral clearance rates (p < 0.001) were found in telbivudine-treated group. No drug resistance developed during the course of treatment. When compared with non-antiviral-treated patients, a significantly higher post-therapeutic estimated glomerular filtration rate (eGFR) was found in the telbivudine-treated group (p < 0.001). In patients with initial eGFR >100 ml/min (n = 34), the median overall survival was significantly longer in the telbivudine-treated group (12.1 vs. 4.9 months; p = 0.042). Conclusion. Preemptive use of telbivudine significantly prevented eGFR deterioration caused by cisplatin-based chemotherapy in HBV-related advanced HCC. In patients with initially sufficient eGFR level, telbivudine treatment was associated with a longer overall survival.

4 January 2022 in Hepatology International
Verified
Journal Article
Closed access
PDF file
Wei-Ting ChenWei-Ting Chen
Wei-Ting Chen
SLShi-Ming Lin
Shi-Ming Lin
WLweichen Lee
weichen Lee
TWTing-Jung Wu
Ting-Jung Wu
CLChen-Chun Lin
Chen-Chun Lin
CYChau-Ting Yeh
Chau-Ting Yeh

5 December 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
PLPuo-Hsien Le
Puo-Hsien Le
CKChcia-Jung Kuo
Chcia-Jung Kuo
YHYi-Chung Hsieh
Yi-Chung Hsieh
TCTsung-Hsing Chen
Tsung-Hsing Chen
CLChih-Lang Lin
Chih-Lang Lin
KLKung-Hao Liang
Kung-Hao Liang
Background: Hepatocellular carcinoma (HCC) is an aggressive solid tumor. HCC occurred at younger and elder ages were considered driven by different oncogenic mechanisms, and they demonstrated distinct clinical courses. Methods: A total of 382 HCC patients treated by surgical resections was analyzed. Results: A univariate-multivariate analysis showed that viral etiology (chronic hepatitis B, C) and the UDP glucuronosyltransferase family 2 member B28 (UGT2B28) genomic variant rs2132039 were independently associated with the age at presentation of HCC (all adjusted P < 0.05). An extensive evaluations of clinicalpathological factors showed that the age (Odds ratio [OR], 1.016; 95% confidence interval [CI], 1.001–1.032; adjusted P = 0.037) and ascites (OR, 3.505; CI, 1.358–9.048; adjusted P = 0.010) were two independent factors associated with this genomic variant. The age was 54.1 ± 14.6 years for patients with the “TT” variant type, and 58.2 ± 13.7 years for those with the “Non-TT” variant type. The age disparity was most prominent in alcoholic patients (OR, 1.079; CI, 1.035–1.125; P < 0.001, age of “TT”, 49.6 ± 12.2; age of “non-TT”, 59.3 ± 10.7). This genomic variant was also associated with age of recurrence (P = 0.025), distant metastasis (P = 0.024) and HCC-related death (P = 0.008) in non-censored patients. Conclusions: An UGT2B28 genomic variant was indicative of the age of HCC presentation, recurrence, distant metastasis and death.